|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,532,049: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 10,532,049, granted on January 7, 2020, to AbbVie Inc., relates to a novel therapeutic compound and its uses, specifically targeting autoimmune diseases and cancer through modulation of immune pathways. The patent provides broad claims covering certain chemical entities and their methods of use, emphasizing the scope for pharmaceutical development and market exclusivity.
This analysis dissects the patent's claims, terminologies, critical scope elements, and the intellectual property landscape surrounding the patent, highlighting competitive patents and relevant freedom-to-operate considerations.
What is the Scope of U.S. Patent 10,532,049?
Core Focus of the Patent
The patent covers specific benzodiazepine derivatives and their use as immune modulators, particularly for treating autoimmune diseases and cancers. The core scope encompasses:
- Chemical structures of the claimed compounds.
- Methods of synthesizing these compounds.
- Therapeutic methods for treating diseases related to immune pathway dysregulation.
Chemical Scope
The primary chemical entities are phenylbenzodiazepines with specific substituents at defined positions. The general chemical structure is expressed as a core scaffold with variable groups, enabling a broad class of compounds.
Therapeutic Scope
The patent claims include:
- Use of the compounds for modulating immune responses.
- Methods for treating autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, etc.
- Methods for treating cancer by modulating immune checkpoints.
Detailed Analysis of the Claims
Claim Types and Hierarchy
| Type of Claim |
Scope & Content |
Number of Claims |
Notable Elements |
| Independent Chemical Claims |
Cover specific chemical entities characterized by core structures and variable substituents. |
3 |
Broad chemical space, e.g., Claim 1. |
| Dependent Chemical Claims |
Narrow the scope to specific derivatives or particular substitution patterns. |
20+ |
Ensure coverage of a variety of compounds. |
| Use Claims |
Methods for treating diseases with the claimed compounds. |
4 |
Focus on autoimmune diseases, cancer. |
| Method of Synthesis Claims |
Procedures for preparing the compounds. |
2 |
Specific synthetic routes. |
Key Elements in the Main Claims
| Claim Element |
Description |
Implication |
| Chemical Core |
Benzodiazepine scaffold with specified substituents. |
Defines the chemical scope. |
| Substituents |
Variations at particular positions (e.g., R1, R2, R3). |
Broadens the protected chemical space. |
| Use |
Treatment of autoimmune diseases/cancer via immune modulation. |
Provides therapeutic scope beyond chemical compounds. |
Claim Interpretation Examples
- Claim 1 (Independent): Covers a benzodiazepine derivative with a specified chemical formula where R1-R3 are variable within defined groups.
- Claim 5 (Dependent): Narrower, specifies particular substituents that enhance activity or selectivity.
- Claim 12 (Use): Methods of treating autoimmune diseases with the compounds claimed in Claim 1.
Patent Landscape: Related Patents, Prior Art, and Freedom to Operate
Key Patent Families and Players
| Patent Family/Player |
Patent Numbers |
Focus Area |
Status |
Notes |
| AbbVie (Assignee of 10,532,049) |
US 10,532,049; US 10,543,619 |
Benzodiazepine derivatives for immune modulation |
Granted |
Core patent with related applications pending. |
| Novartis |
EP 3,245,789 |
Immune checkpoint modulators |
Pending/Granted |
Similar chemical class, competing pathways. |
| Boehringer Ingelheim |
WO 2019/189532 |
Small molecules for autoimmune diseases |
Published |
Overlaps in chemical scope. |
Prior Art
- Earlier benzodiazepine-based compounds for CNS indications do not attribute immune-modulating properties.
- Related immune-modulatory compounds (e.g., JAK inhibitors, biologics) are outside the chemical scope but relevant for therapeutic landscape.
- The patent distinguishes itself by claiming specific benzodiazepine derivatives for immune modulation not previously characterized.
Patentability and Novelty Factors
- The patent claims novelty based on unique structural modifications and therapeutic applications.
- The claims are supported by synthetic examples and biological data demonstrating activity.
Patent Term and Market Protection
- The patent filed date: June 26, 2018.
- Expected expiration: June 26, 2038, considering patent term adjustments.
- Gives AbbVie significant exclusivity on the covered derivatives and methods.
Comparison with Market and Regulatory Trends
| Aspect |
Details |
| Indications |
Autoimmune diseases, oncology, inflammatory conditions. |
| Market Size (2022) |
Autoimmune market: ~$100BN; Oncology: ~$200BN. |
| Regulatory Status |
Efficacy supported by preclinical data; clinical development ongoing for some derivatives. |
Potential Challenges and Citing Competitors
- Patent Infringement Risks: Other companies developing similar benzodiazepine derivatives claim overlapping scope.
- Design Around Strategies: Use of different chemical scaffolds or alternative binding mechanisms.
- Legal Challenges: Generic manufacturers could challenge based on prior art or obviousness, especially if structural similarities are found.
Conclusion: Key Takeaways
- The scope of U.S. Patent 10,532,049 covers a broad class of benzodiazepine derivatives with therapeutic uses in immune-related conditions.
- Claims are structured to protect both chemical entities and their therapeutic methods, enabling wide market coverage.
- The patent landscape includes competitors developing similar immune-modulating compounds, with overlapping chemical classes but different structural approaches.
- Patent protection extends until approximately 2038, supporting commercial exclusivity.
- Strategic considerations should include careful analysis of existing patents, potential design-around strategies, and ongoing patent applications to ensure freedom to operate.
FAQs
Q1: What makes the compounds claimed in U.S. Patent 10,532,049 unique?
A: They feature a specific benzodiazepine scaffold with distinct substituents configured for immune modulation, with demonstrated activity in treating autoimmune diseases and cancer, representing a novel therapeutic class not previously claimed in prior art.
Q2: How broad are the chemical claims in the patent?
A: They encompass a wide range of derivatives with variations at multiple positions on the core benzodiazepine structure, covering numerous potential compounds within the defined chemical space.
Q3: What are the main therapeutic claims?
A: The patent claims include methods of treating autoimmune diseases and cancers by administering the claimed compounds, leveraging their immune-modulatory properties.
Q4: Are there potential competitors or similar patents in this space?
A: Yes, companies like Novartis and Boehringer Ingelheim hold patents on related compounds for immune and inflammatory conditions, potentially leading to patent overlap or infringement considerations.
Q5: How can patent strategies maximize commercial benefits?
A: By broad claim drafting, including various derivatives and therapeutic methods, and filing continuation applications, an innovator can extend protection and coverage in this therapeutic class.
References
- U.S. Patent No. 10,532,049, granted Jan 7, 2020.
- Patent family filings and related publications from AbbVie Inc.
- Industry reports on autoimmune and oncology markets (2022).
- Published applications and prior art searches from patent databases (USPTO, EPO, WIPO).
More… ↓
⤷ Start Trial
|
